Novo stock surges on rival’s weak sales data

Novo Nordisk shares rose 5.4 percent on Friday following sales data from competitor Eli Lilly. Data reveals that Eli Lilly’s weight-loss pill, Foundayo, recorded 3,707 prescriptions in its second week, while Novo Nordisk’s oral version of Wegovy saw 18,410 prescriptions in the same period....